M1 agonists as a Potential Disease-Modifying Therapy for Alzheimer's Disease

Current Alzheimer Research

Volumn 6, Issue 2, 2009, Pages 112-117

  Caccamo, Antonella ^a   Fisher, Abraham ^b   Laferla, Frank M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF 267B; AMYLOID BETA PROTEIN; CEVIMELINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; DICYCLOVERINE; MUSCARINIC M1 RECEPTOR AGONIST; NICOTINIC AGENT; RECEPTOR SUBTYPE; TALSACLIDINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; MUSCARINIC AGONISTS; RECEPTOR, MUSCARINIC M1; SIGNAL TRANSDUCTION;

EID: 64549132538     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509787602915     Document Type: Review

References (64)

1. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. Science 297:353-6 (2002).
2. Ballatore C, Lee VM, and Trojanowski JQ. Tau-mediated neurode-generation in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-72 (2007).
3. Avila J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett 580:2922-7 (2006).
4. Davies P and Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403 (1976).
5. Koch HJ, Szecsey A, and Haen E. NMDA-antagonism (meman-tine):an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. Curr Pharm Des 10:253-9 (2004).
6. Camps P and Munoz-Torrero D. Cholinergic drugs in pharma-cotherapy of Alzheimer's disease. Mini Rev Med Chem 2:11-25 (2002).
7. Ibach B and Haen E. Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Des 10:231-51 (2004).
8. Winblad B and Jelic V. Long-term treatment of Alzheimer disease:efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 18 (Suppl 1):S2-8 (2004).
9. Mesulam MM, Mufson EJ, Wainer BH, and Levey AI. Central cholinergic pathways in the rat:an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10:1185-201 (1983).
10. Baxter MG and Chiba AA. Cognitive functions of the basal fore-brain. Curr Opin Neurobiol 9:178-83 (1999).
11. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 3:102-14 (2002).
12. Gotti C and Clementi F. Neuronal nicotinic receptors:from structure to pathology. Prog Neurobiol 74:363-96 (2004).
13. Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lind-strom J, et al. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease:histotopog-raphical correlation with amyloid plaques and hyperphosphory-lated-tau protein. Eur J Neurosci 11:2551-65 (1999).
14. Nordberg A, Adem A, Hardy J and Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci Lett 86:317-21 (1988).
15. Burghaus L, Schutz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76:385-8 (2000).
16. Sparks DL, Beach TG and Lukas RJ. Immunohistochemical localization of nicotinic beta2 and alpha4 receptor subunits in normal human brain and individuals with Lewy body and Alzheimer's disease:preliminary observations. Neurosci Lett 256:151-4 (1998).
17. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci USA 102:3046-51 (2005).
18. Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 81:655-8 (2002).
19. Hellstrom-Lindahl E, Court J, Keverne J, Svedberg M, Lee M, Marutle A, et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 19:2703-10 (2004).
20. Ulrich J, Johannson-Locher G, Seiler WO and Stahelin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol 94:450-4 (1997).
21. Levey AI, Kitt CA, Simonds WF, Price DL and Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218-26 (1991).
22. Wei J, Walton EA, Milici A and Buccafusco JJ. m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J Neuro-chem 63:815-21 (1994).
23. Felder CC. Muscarinic acetylcholine receptors:signal transduction through multiple effectors. FASEB J 9:619-25 (1995).
24. Nordberg A, Alafuzoff I and Winblad B. Nicotinic and muscarinic subtypes in the human brain:changes with aging and dementia. J Neurosci Res 31:103-11 (1992).
25. Ladner CJ and Lee JM. Pharmacological drug treatment of Alzheimer disease:the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57:719-31 (1998).
26. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. Curr Alzheimer Res 4:577-80 (2007).
27. Musial A, Bajda M and Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem 14:2654-79 (2007).
28. Nitsch RM, Slack BE, Wurtman RJ and Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-7 (1992).
29. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 268:22959-62 (1993).
30. Wolf BA, Wertkin AM, Jolly YC, Yasuda RP, Wolfe BB, Konrad RJ, et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 270:4916-22 (1995).
31. Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D and Fisher A. Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. Eur J Pharmacol 267:21-31 (1994).
32. Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z, et al. Amyloid precursor protein secretion via muscarinic receptors:reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Commun 203:652-8 (1994).
33. Muller DM, Mendla K, Farber SA and Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 60:985-91 (1997).
34. Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS and DeLapp NW. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 57:1183-90 (1995).
35. Qiu Y, Chen HZ, Wu XJ and Jin ZJ. 6beta-acetoxy nortropane regulated processing of amyloid precursor protein in CHOm1 cells and rat brain. Eur J Pharmacol 468:1-8 (2003).
36. Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, et al. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem 71:2094-103 (1998).
37. Pittel Z, Heldman E, Barg J, Haring R and Fisher A. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 742:299-304 (1996).
38. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 89:10075-8 (1992).
39. Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease:implications in future therapy. J Mol Neurosci 20:349-56 (2003).
40. Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I and Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 66:877-80 (1996).
41. Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF and Lovestone S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm 107:1201-12 (2000).
42. Isagawa T, Mukai H, Oishi K, Taniguchi T, Hasegawa H, Kawamata T, et al. Dual effects of PKNalpha and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3beta. Biochem Biophys Res Commun 273:209-12 (2000).
43. Stambolic V and Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303 ( Pt 3):701-4 (1994).
44. Genis I, Gordon I, Sehayek E and Michaelson DM. Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett 199:5-8 (1995).
45. Gordon I, Grauer E, Genis I, Sehayek E and Michaelson DM. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 199:1-4 (1995).
46. Genis I, Fisher A and Michaelson DM. Site-specific dephosphory-lation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem 72:206-13 (1999).
47. Fisher A, Brandeis R, Chapman S, Pittel Z and Michaelson DM. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J Neurochem 70:1991-7 (1998).
48. Beach TG, Walker DG, Potter PE, Sue LI and Fisher A. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res 905:220-3 (2001).
49. Beach T, Walker D, Potter L, Sue L, Scott S, Layne K, et al. Immunotoxin lesion of the cholinergic nucleus basalis causes Abeta deposition:towards a physiologic animal model of Alzheimer's disease. Curr Med Chem 3:233-43 (2003).
50. Lin L, Georgievska B, Mattsson A and Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci USA 96:12108-13 (1999).
51. Seo H, Ferree AW and Isacson O. Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. Eur J Neurosci 15:498-506 (2002).
52. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles:intracellular Abeta and synaptic dysfunction. Neuron 39:409-21 (2003).
53. Billings LM, Oddo S, Green KN, McGaugh JL and LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45:675-88 (2005).
54. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49:671-82 (2006).
55. Liskowsky W and Schliebs R. Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopola-mine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 24:149-56 (2006).
56. Wall SJ, Yasuda RP, Hory F, Flagg S, Martin BM, Ginns EI, et al. Production of antisera selective for m1 muscarinic receptors using fusion proteins:distribution of m1 receptors in rat brain. Mol Pharmacol 39:643-9 (1991).
57. Messer WS, Jr., Bohnett M and Stibbe J. Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci Lett 116:184-9 (1990).
58. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits:implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA 93:13541-6 (1996).
59. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 11 (Suppl 4):S16-22 (1997).
60. Eglen RM. Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem 43:105-36 (2005).
61. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, et al. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann NY Acad Sci 920:285-91 (2000).
62. Nitsch RM, Deng M, Tennis M, Schoenfeld D and Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48:913-8 (2000).
63. Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10:1-6 (2003).
64. Messer WS, Jr. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 19:187-93 (2002).